Open AccessNanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma
Author(s) -
Adriana L. da Silva,
Gisele P. Oliveira,
Namho Kim,
Fernanda F. Cruz,
Jamil Z. Kitoko,
Natália G. Blanco,
Sabrina V. Martini,
Justin Hanes,
Patrícia R. M. Rocco,
Jung Soo Suk,
Marcelo M. Morales
Publication year - 2020
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.aay7973
Subject(s) - medicine , asthma , mucus , genetic enhancement , fibrosis , inflammation , lung , disease , immunology , cystic fibrosis , pulmonary fibrosis , pathology , gene , biology , ecology , biochemistry
Nanoparticle-based thymulin gene therapy provides near-complete resolution of key pathology of chronic allergic asthma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom